Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 172,208 shares of the business’s stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $9.45, for a total transaction of $1,627,365.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The shares were sold at an average price of $9.50, for a total transaction of $973,180.00.

Shares of Recro Pharma, Inc. (NASDAQ:REPH) traded up $0.05 during trading hours on Friday, reaching $9.38. 123,700 shares of the company’s stock were exchanged, compared to its average volume of 118,569. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. Recro Pharma, Inc. has a one year low of $5.81 and a one year high of $10.17.

COPYRIGHT VIOLATION WARNING: “Recro Pharma, Inc. (REPH) Major Shareholder Sells $1,627,365.60 in Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/recro-pharma-inc-reph-major-shareholder-sells-1627365-60-in-stock/1724469.html.

A number of large investors have recently modified their holdings of REPH. OxFORD Asset Management LLP increased its stake in Recro Pharma by 364.3% during the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock worth $1,430,000 after purchasing an additional 159,619 shares during the period. State Street Corp purchased a new stake in Recro Pharma during the second quarter worth about $1,047,000. Northern Trust Corp increased its stake in Recro Pharma by 428.5% during the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after purchasing an additional 144,676 shares during the period. Dimensional Fund Advisors LP increased its stake in Recro Pharma by 787.4% during the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock worth $911,000 after purchasing an additional 114,960 shares during the period. Finally, JT Stratford LLC purchased a new stake in Recro Pharma during the second quarter worth about $704,000. Institutional investors own 64.97% of the company’s stock.

A number of research analysts have commented on REPH shares. Zacks Investment Research cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Roth Capital set a $20.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a research report on Friday, October 27th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Recro Pharma presently has a consensus rating of “Buy” and an average target price of $12.88.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.